寶藿苷I

分析標(biāo)準(zhǔn)品,含量96.0%，可溯源

Baohuoside I

CAS號(hào)：113558-15-9

分子式：C27H30O10

分子量：514.52

MDL：MFCD15071140

別名：淫羊藿次苷II; 寶藿苷 I; 寶藿苷Ⅰ; 淫羊藿次苷II;

 產(chǎn)品介紹

熔點(diǎn)： 202-203°C

沸點(diǎn)： 759.4°C at 760mmHg

比旋光度： (c, 0.09 in MeOH)-121

外觀： 黃色針狀結(jié)晶

溶解性： DMSO  :  ≥  32  mg/mL (62.19  mM)

儲(chǔ)存條件： 2-8℃

注意： 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

參考文獻(xiàn)(5篇)

5. [IF=2.5] Zheng Junzuo et al."Pharmacokinetics of seven major components in Aβ1-42-treated rats after oral administration of an aqueous extract of Curculiginis Rhizoma and Epimedii Folium."Journal of Natural Medicines.2024 Nov;:1-16

4. [IF=6.1] Xiuchun Li et al."Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps."LIFE SCIENCES".2024 Jun;346:122648

3. [IF=6] Dong Xie et al."Pharmacodynamic material basis and mechanism of Tenghuang Jiangu Wan on osteoarthritis using UPLC-Q-TOF-MS integrated with target network pharmacology."Arabian Journal of Chemistry".2024 Apr;17:105711

2. [IF=1.6] Liu Huimin et al."Identification and Characterization of the Chemical Constituents of Qianlie Shule Capsules by UPLC-Q-Orbitrap-MS/MS."JOURNAL OF AOAC INTERNATIONAL".2024 Feb;:

1. [IF=8.4] Ting An et al."De novo biosynthesis of anticarcinogenic icariin in engineered yeast."METABOLIC ENGINEERING.2023 Nov;80:207

寶藿苷I

分析標(biāo)準(zhǔn)品,含量96.0%，可溯源

Baohuoside I

CAS號(hào)：113558-15-9

分子式：C27H30O10

分子量：514.52

MDL：MFCD15071140

別名：淫羊藿次苷II; 寶藿苷 I; 寶藿苷Ⅰ; 淫羊藿次苷II;

產(chǎn)品介紹

熔點(diǎn)： 202-203°C

沸點(diǎn)： 759.4°C at 760mmHg

比旋光度： (c, 0.09 in MeOH)-121

外觀： 黃色針狀結(jié)晶

溶解性： DMSO  :  ≥  32  mg/mL (62.19  mM)

儲(chǔ)存條件： 2-8℃

注意： 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

參考文獻(xiàn)(5篇)

5. [IF=2.5] Zheng Junzuo et al."Pharmacokinetics of seven major components in Aβ1-42-treated rats after oral administration of an aqueous extract of Curculiginis Rhizoma and Epimedii Folium."Journal of Natural Medicines.2024 Nov;:1-16

4. [IF=6.1] Xiuchun Li et al."Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps."LIFE SCIENCES".2024 Jun;346:122648

3. [IF=6] Dong Xie et al."Pharmacodynamic material basis and mechanism of Tenghuang Jiangu Wan on osteoarthritis using UPLC-Q-TOF-MS integrated with target network pharmacology."Arabian Journal of Chemistry".2024 Apr;17:105711

2. [IF=1.6] Liu Huimin et al."Identification and Characterization of the Chemical Constituents of Qianlie Shule Capsules by UPLC-Q-Orbitrap-MS/MS."JOURNAL OF AOAC INTERNATIONAL".2024 Feb;:

1. [IF=8.4] Ting An et al."De novo biosynthesis of anticarcinogenic icariin in engineered yeast."METABOLIC ENGINEERING.2023 Nov;80:207

從2011年開始我們致力于在生命科學(xué)領(lǐng)域、生物醫(yī)學(xué)實(shí)驗(yàn)技術(shù)及論文潤(rùn)色服務(wù)，協(xié)助客戶各類實(shí)驗(yàn)服務(wù)及論文潤(rùn)色十多年，是您值得信賴的科研合作伙伴!

如果您受時(shí)間、試驗(yàn)條件等限制而無(wú)法完成您的課題研究，歡迎您與我們聯(lián)系。

實(shí)驗(yàn)技術(shù)服務(wù)：